| Field | Value |
|---|---|
| Trial Name | KEYNOTE-177 |
| DOI | https://doi.org/10.1016/S1470-2045(21)00064-4 |
| Diagnosis | Metastatic colorectal cancer, microsatellite instability-high, mismatch repair-deficient |
| Drugs | Pembrolizumab 200 mg |
| Line Of Therapy | First-line therapy |
| Regimen | Pembrolizumab every 3 weeks |
| Primary End Point | Progression-free survival |
| Secondary End Point | Overall survival, HRQOL outcomes |
| Competitor Arm | Chemotherapy (mFOLFOX6 or FOLFIRI) with or without bevacizumab or cetuximab |
| Efficacy | Statistically significant and clinically meaningful improvements in progression-free survival |
| Response Types | |
| Time To Response | |
| Surveillance | HRQOL assessments |
| Subsets | |
| Adverse Events | |
| Others | NCT02563002 |
| Conclusion | Pembrolizumab monotherapy provides clinically meaningful improvements in HRQOL compared to chemotherapy, supporting its use as a first-line treatment option for this population |